Ovid Therapeutics Stock Performance
| OVID Stock | USD 1.05 0.01 0.94% |
The company holds a Beta of 2.34, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ovid Therapeutics will likely underperform. At this point, Ovid Therapeutics has a negative expected return of -0.26%. Please make sure to check Ovid Therapeutics' day median price, relative strength index, as well as the relationship between the kurtosis and maximum drawdown , to decide if Ovid Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Ovid Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
1 | Acquisition by Perone Thomas Michael of 175000 shares of Ovid Therapeutics at 2.72 subject to Rule 16b-3 | 08/30/2024 |
2 | Disposition of 70000 shares by Alexander Margaret A. of Ovid Therapeutics at 3.73 subject to Rule 16b-3 | 09/09/2024 |
3 | Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth - StockTitan | 09/11/2024 |
4 | Ovid stock gets boost from promising OV329 toxicity profile - B.Riley - Investing.com | 09/27/2024 |
5 | Ovid Therapeutics Inc. Given Consensus Recommendation of Moderate Buy by Analysts | 10/11/2024 |
6 | Acquisition by Friedman Bart of 69424 shares of Ovid Therapeutics subject to Rule 16b-3 | 10/24/2024 |
7 | Acquisition by Williams Douglas E of 13250 shares of Ovid Therapeutics at 5.29 subject to Rule 16b-3 | 10/25/2024 |
8 | Explainer-How Trumps second administration affects business Musk, tariffs and more | 11/06/2024 |
9 | Ovid Therapeutics earnings beat, revenue topped estimates | 11/12/2024 |
10 | How controversial is Trumps pick of RFK Jr as US health secretary | 11/15/2024 |
11 | B. Riley Predicts Reduced Earnings for Ovid Therapeutics | 11/20/2024 |
| Begin Period Cash Flow | 44.9 M |
Ovid |
Ovid Therapeutics Relative Risk vs. Return Landscape
If you would invest 130.00 in Ovid Therapeutics on August 25, 2024 and sell it today you would lose (25.00) from holding Ovid Therapeutics or give up 19.23% of portfolio value over 90 days. Ovid Therapeutics is currently does not generate positive expected returns and assumes 3.7889% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Ovid, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ovid Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ovid Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ovid Therapeutics, and traders can use it to determine the average amount a Ovid Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0678
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OVID |
Estimated Market Risk
| 3.79 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ovid Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ovid Therapeutics by adding Ovid Therapeutics to a well-diversified portfolio.
Ovid Therapeutics Fundamentals Growth
Ovid Stock prices reflect investors' perceptions of the future prospects and financial health of Ovid Therapeutics, and Ovid Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ovid Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (76.45) % | ||||
| Current Valuation | 26.92 M | ||||
| Shares Outstanding | 71.01 M | ||||
| Price To Earning | 1.11 X | ||||
| Price To Book | 0.98 X | ||||
| Price To Sales | 118.03 X | ||||
| Revenue | 391.69 K | ||||
| Gross Profit | 1.5 M | ||||
| EBITDA | (58.71 M) | ||||
| Net Income | (52.34 M) | ||||
| Cash And Equivalents | 152.37 M | ||||
| Cash Per Share | 2.16 X | ||||
| Total Debt | 16 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 16.94 X | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | (45.78 M) | ||||
| Earnings Per Share | (0.46) X | ||||
| Market Capitalization | 74.56 M | ||||
| Total Asset | 144.03 M | ||||
| Retained Earnings | (277.87 M) | ||||
| Working Capital | 98.12 M | ||||
| Current Asset | 74.21 M | ||||
| Current Liabilities | 5.13 M | ||||
About Ovid Therapeutics Performance
By analyzing Ovid Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Ovid Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ovid Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ovid Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.4 K | 1.3 K | |
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.45) | (0.47) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.60) | (0.63) |
Things to note about Ovid Therapeutics performance evaluation
Checking the ongoing alerts about Ovid Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ovid Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ovid Therapeutics generated a negative expected return over the last 90 days | |
| Ovid Therapeutics has some characteristics of a very speculative penny stock | |
| Ovid Therapeutics has high historical volatility and very poor performance | |
| Ovid Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 391.69 K. Net Loss for the year was (52.34 M) with profit before overhead, payroll, taxes, and interest of 1.5 M. | |
| Ovid Therapeutics currently holds about 152.37 M in cash with (45.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ovid Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: B. Riley Predicts Reduced Earnings for Ovid Therapeutics |
- Analyzing Ovid Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ovid Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Ovid Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ovid Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ovid Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ovid Therapeutics' stock. These opinions can provide insight into Ovid Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ovid Stock analysis
When running Ovid Therapeutics' price analysis, check to measure Ovid Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ovid Therapeutics is operating at the current time. Most of Ovid Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ovid Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ovid Therapeutics' price. Additionally, you may evaluate how the addition of Ovid Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |